Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical innovator focused on developing oral non-statin therapies for cardiovascular patients with elevated LDL cholesterol. This dedicated news hub provides investors and healthcare professionals with timely updates on the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access ESPR’s latest press releases covering FDA approvals, clinical trial results, and partnership announcements with global pharmaceutical leaders. Our curated collection includes earnings reports, research breakthroughs, and market expansion updates—all essential for understanding the company’s position in cholesterol management innovation.
Discover updates on bempedoic acid developments, international licensing agreements, and R&D pipeline progress. This resource serves as your primary source for tracking ESPR’s mission to address unmet needs in cardiovascular care through targeted therapeutic solutions.
Bookmark this page for streamlined access to verified Esperion Therapeutics announcements. Check regularly for new insights into one of biopharma’s most focused approaches to LDL-C reduction without statin-related limitations.
Esperion (NASDAQ: ESPR) announced that its partner Otsuka Pharmaceutical has received approval from Japanese regulators to market NEXLETOL for treating hypercholesterolemia and familial hypercholesterolemia in Japan. This approval marks NEXLETOL's entry into the third-largest global market for cardiovascular prevention.
The approval triggers milestone payments to Esperion under their partnership agreement with Otsuka, which includes tiered royalties of 15-30% on net sales in Japan and additional sales milestone payments. NEXLETOL, a non-statin LDL-C lowering therapy, is now approved across the U.S., Europe, and Japan, establishing a strong global presence for Esperion's cholesterol treatment.
Esperion (NASDAQ: ESPR) announced that bempedoic acid has received a prestigious Level 1a recommendation in the 2025 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for Dyslipidaemias management.
The guidelines specifically recommend bempedoic acid as the only non-statin newly recommended treatment for LDL-C lowering and cardiovascular risk reduction. Key recommendations include using bempedoic acid for patients unable to take statins (Class I, Level A/B) and considering its addition to maximum statin doses with/without ezetimibe for high-risk patients (Class IIa, Level C).
This recognition supports Esperion's strategic development of oral triple combination therapies, aligning with the guidelines' emphasis on earlier, aggressive combination therapy. The company's portfolio includes NEXLETOL (bempedoic acid), NEXLIZET (bempedoic acid and ezetimibe), and upcoming triple combinations with atorvastatin or rosuvastatin.
Esperion (NASDAQ: ESPR), a commercial stage biopharmaceutical company, announced its participation in two upcoming investor conferences in September 2025: the Cantor Global Healthcare Conference on September 3 at 9:45 a.m. ET and the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 2:00 p.m. ET.
The company specializes in FDA-approved oral, once-daily, non-statin medicines for patients with elevated LDL-C and cardiovascular disease risk, supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through partnerships and pipeline advancement.
Esperion (NASDAQ: ESPR) has announced the granting of 73,500 restricted stock units (RSUs) to 12 new employees under its 2017 Inducement Equity Incentive Plan. The RSUs will vest 25% after one year, with the remaining 75% vesting in twelve equal quarterly installments thereafter, contingent on continued employment.
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C. The company is also advancing its next-generation ATP citrate lyase inhibitor (ACLYi) program, leveraging new insights for developing highly potent and specific inhibitors.
Esperion (NASDAQ: ESPR) reported strong Q2 2025 financial results, with total revenue growing 12% year-over-year to $82.4 million. U.S. net product revenue increased 42% to $40.3 million, while total retail prescription equivalents grew 10% from Q1.
Key achievements include settlement agreements with three ANDA filers protecting NEXLETOL® until 2040, and the company's first-ever quarter of operating income ($15.0 million). Esperion expanded globally through partnerships in Japan, Europe, Canada, Israel, and Australia/New Zealand, with European royalty revenue increasing 30% sequentially to $13.6 million.
The company expects to achieve sustainable profitability beginning in Q1 2026 and maintains its 2025 operating expense guidance of $215-235 million.
Esperion (NASDAQ: ESPR) has scheduled its second quarter 2025 financial results announcement for August 5, 2025, before market open. The company will host a webcast at 8:00 a.m. ET to discuss the results and provide business updates.
Esperion is a commercial-stage biopharmaceutical company developing FDA-approved oral, once-daily, non-statin medicines for cardiovascular disease patients with elevated LDL-C. Their medications are supported by the 14,000-patient CLEAR Cardiovascular Outcomes Trial. The company is also advancing its next-generation program focusing on ATP citrate lyase inhibitors (ACLYi) development.
Esperion (NASDAQ: ESPR) has reached a settlement agreement with Accord Healthcare Inc. regarding patent litigation over NEXLETOL, a bempedoic acid medication. Under the agreement, Accord Healthcare has committed not to market a generic version of NEXLETOL in the United States before April 19, 2040, except under specific limited circumstances.
The company continues to pursue patent litigation against several other defendants, including Alkem Laboratories, Aurobindo Pharma, Dr. Reddy's Laboratories, MSN Pharmaceuticals, Renata Limited, and Sandoz. The outcome of these ongoing patent disputes remains uncertain regarding potential generic versions of NEXLETOL and NEXLIZET entering the U.S. market before 2040.
Esperion (NASDAQ: ESPR) has appointed Craig Thompson, current CEO of Cerevance, to its Board of Directors as an independent director, expanding the board to eight members. Thompson brings over 20 years of biopharmaceutical industry leadership experience and currently serves as CEO of Cerevance, a clinical-stage biotechnology company.
Thompson's extensive experience includes leadership roles at several pharmaceutical companies, notably serving as President & CEO of Neurana Pharmaceuticals, COO at Tetraphase Pharmaceuticals, and Chief Commercial Officer at Trius Therapeutics, where he was involved in its $700+ million acquisition by Cubist Pharmaceuticals. His background also includes senior positions at Pfizer and Merck & Co., where he led significant cardiovascular product initiatives.
Esperion (NASDAQ: ESPR) has announced its participation in two major investor conferences in June 2025: the Jefferies Global Healthcare Conference in New York on June 4 at 1:25 p.m. ET, and the Goldman Sachs Global Healthcare Conference in Miami on June 9 at 10:40 a.m. ET.
The company, a commercial stage biopharmaceutical firm, specializes in FDA-approved oral, once-daily, non-statin medicines for patients with cardiovascular disease and elevated LDL-C. Their medications are supported by the CLEAR Cardiovascular Outcomes Trial involving nearly 14,000 patients. Esperion is also developing next-generation ATP citrate lyase inhibitors (ACLYi) and expanding globally through commercial execution and international partnerships.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
